A61K 38 - Medicinal preparations containing peptides

Patents for A61K 38 - Medicinal preparations containing peptides (316,240)
08/2006
08/24/2006	WO2006088624A2 Stabilized compositions containing natriuretic peptides
08/24/2006	WO2006088576A2 Polypeptide formulations and methods for making, using and characterizing them
08/24/2006	WO2006088503A1 Delivery of enzymes to the brain
08/24/2006	WO2006088491A2 Methods and compositions related to the modulation of intercellular junctions
08/24/2006	WO2006088336A1 Sustained release composition of protein drug
08/24/2006	WO2006088198A1 Method of producing protein by using hamster igf-1
08/24/2006	WO2006088010A1 Antimicrobial peptide and use thereof
08/24/2006	WO2006087756A2 Poly-epitope peptide derived from thymidylate synthase having immunological and anti-tumour activity
08/24/2006	WO2006087624A1 Pharmaceutical composition and relative use for the treatment and prevention of prostate tumour
08/24/2006	WO2006087579A1 Treatment for neurodegeneration
08/24/2006	WO2006087550A2 Amyloid-binding peptides, analogues and uses thereof
08/24/2006	WO2006087533A2 Ricin-binding peptides and methods for use thereof
08/24/2006	WO2006087363A1 Cosmetic use of at least one natural ac-n-ser-asp-lys-pro-tetrapeptide or one of its analogues as agent for slowing down loss of hair and/or stimulating hair growth
08/24/2006	WO2006087340A2 Highly potent full and partial agonists and antagonists of the nociceptin/orphanin fq receptor
08/24/2006	WO2006087001A1 Template-fixed beta-hairpin peptidomimetics with protease inhibitory activity
08/24/2006	WO2006086891A1 Insulin-like growth factor binding protein-4 compounds and methods for inhibiting angiogenesis and tumor growth in mammalian cells
08/24/2006	WO2006086823A1 Molecules and chimeric molecules thereof
08/24/2006	WO2006086822A1 A molecule and chimeric molecules thereof
08/24/2006	WO2006076673A3 Use of il-i antagonists to treat polymyalgia rheumatica and giant cell arteritis
08/24/2006	WO2006072888A3 Continuous administration of epitopes derived from protein present in atherosclerotic plaque for the treatment of atherosclerosis
08/24/2006	WO2006071451A9 Compounds that prevent macrophage apoptosis and uses thereof
08/24/2006	WO2006067635A3 USE OF Ϝδ T LYMPHOCYTE ACTIVATORS AS VACCINE ADJUVANT
08/24/2006	WO2006066317A8 Controlled release of biological entities
08/24/2006	WO2006063864A3 Compositions for preventing, reducing or treating keratinocyte-mediated inflammation
08/24/2006	WO2006063596A3 A composition comprising pp for the treatment of gastrointestinal disorders
08/24/2006	WO2006061714A3 Anticoronaviral compounds and compositions, their pharmaceutical uses and materials for their synthesis
08/24/2006	WO2006056987A3 Leptin antagonists
08/24/2006	WO2006056823A8 Modulating retinal pigmented epithelium permeation by inhibiting or activating vegfr-1
08/24/2006	WO2006055417A3 Methods for the therapeutic use of cyclosporine components
08/24/2006	WO2006053299A3 Site-directed modification of fviii
08/24/2006	WO2006043079A3 Compositions and methods for the control of mammary cell number
08/24/2006	WO2006039621A3 Novel modification of immunomodulatory protein
08/24/2006	WO2006039327A3 Methods of treatment or prophylaxis of amyloidogenic diseases of the eye or optic nerve
08/24/2006	WO2006038131A3 Inhibitors of infection
08/24/2006	WO2006034032A3 Biomarkers for breast cancer
08/24/2006	WO2006033713A3 Methods for ciprofloxacin inhalation
08/24/2006	WO2006013388A3 Materials and methods for modulating signalling by alpha-v integrin molecules
08/24/2006	WO2006012525A3 Non-diabetogenic therapy using a 20kda placental growth hormone variant
08/24/2006	WO2006007565A8 Cd40 variants skipping exon 5
08/24/2006	WO2005120581A3 Gene therapy for neurometabolic disorders
08/24/2006	WO2005094265A3 Self assembling activation agents targeted using active drug release
08/24/2006	WO2005086640A3 Liquefaction processes
08/24/2006	WO2005081945A3 Diagnosis or treatment of endothelial cell dysfunction related diseases
08/24/2006	WO2005051973A3 Peptides derived from natural cytotoxicity receptors and methods of use thereof
08/24/2006	WO2005030134A3 Relationship of a specific metabolite to insulin resistance
08/24/2006	WO2004106491A3 Angiogenin-based hiv-1 therapies
08/24/2006	WO2004082603A3 Modified heat-generating cosmetic compositions
08/24/2006	WO2004043397A3 Compositions and methods for the treatment of rheumatoid arthritis
08/24/2006	WO2004016734A3 Nucleic acids and corresponding proteins entitled 282p1g3 useful in treatment and detection of cancer
08/24/2006	WO2003070193A3 RNA interference mediated inhibition of HIV gene expression using short interfering nucleic acid (siNA)
08/24/2006	US20060191027 Cystine-knot polypeptides: Cloaked-2 molecules and uses thereof
08/24/2006	US20060189813 Amidating a 2,3,4,5,6,7-hexahydro-1H-indole-2-carboxylic acid or ester with a 2-substituted propionyl chloride in the presence of a base; amination with ethyl 2-aminovaleraate, and hydrogenation; uses readily obtainable starting materials; 1-(2-substituted propionyl)hexahydroindole-2-carboxylates
08/24/2006	US20060189810 Novel sulfonamide inhibitors of aspartyl protease
08/24/2006	US20060189793 Methods and compositions for inhibiting neoplastic cell growth
08/24/2006	US20060189792 Neisseria meningitidis antigenic polypeptides, corresponding polynucleotides and protective antibodies
08/24/2006	US20060189695 External preparation for improving coital function
08/24/2006	US20060189687 decreased toxicity; for cytolysis of tumors; gene therapy; immunotherapy
08/24/2006	US20060189657 Difluoroalkyl-subsituted amides such as morpholine-4-carboxylic acid {(S)-1-[(S)-1-(3-cyclopropyl-1,2,4-oxadiazole-5-carbonyl)-propylcarbamoyl]-3,3-difluoro-butyl}-amide; diseases associated wtih cathepsin S, K, and B such as neurodegenerative diseases, osteoporosis, emphysema, viral infection, cancer
08/24/2006	US20060189640 Method of increasing drug oral bioavailability and compositions of less toxic orotate salts
08/24/2006	US20060189611 Amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors
08/24/2006	US20060189609 1, 8-Naphthyridine derivatives and their use to treat diabetes and related disorders
08/24/2006	US20060189584 Pharmaceutical combinations
08/24/2006	US20060189563 Detection and modulation of IAPS and NAIP for the diagnosis and treatment of proliferative disease
08/24/2006	US20060189558 Delivery of substances to cells
08/24/2006	US20060189544 Integrin-Mediated drug targeting
08/24/2006	US20060189543 Compositions and methods for the treatment of leukemia
08/24/2006	US20060189542 Preventive or therapeutic composition for viral infectious disease
08/24/2006	US20060189541 Methods of treating dry eye disorders
08/24/2006	US20060189540 Detection of toxic gluten oligopeptides refractory to digestion and antibodies and T cells responsive thereto can be used to diagnose Celiac Sprue
08/24/2006	US20060189539 Novel GnRH analogues with antitumour effects and pharmaceutical compositions thereof
08/24/2006	US20060189538 Peptides and nucleic acids of the cathelicidin family, derived from fish, and uses thereof
08/24/2006	US20060189537 Peptides for detection of antibody to Ehrlichia ewingii
08/24/2006	US20060189536 Treating the effects of nicotine
08/24/2006	US20060189535 Combination treatment using exendins and thiazolidinediones
08/24/2006	US20060189534 Compounds useful in inhibiting vascular leakage, inflammation and fibrosis and methods of making and using same
08/24/2006	US20060189533 Stable pharmaceutical dosage forms of teriparatide
08/24/2006	US20060189532 Use of calcitonin and calcitonin-like peptides to treat and prevent multiple sclerosis
08/24/2006	US20060189531 Thrombopoietic compounds
08/24/2006	US20060189530 Neuropeptide Y receptor Y5 and nucleic acid sequences
08/24/2006	US20060189529 Modified human growth hormone
08/24/2006	US20060189528 Osteoprotegerin variant proteins
08/24/2006	US20060189527 Methods of treating disease with random copolymers
08/24/2006	US20060189526 Compositions containing an intestinal trefoil peptide and a mucoadhesive
08/24/2006	US20060189525 DADD, death activator death domain protein
08/24/2006	US20060189524 Pharmaceutical compositions based on anticholinergics and pegsunercept
08/24/2006	US20060189523 Use of effectors of glutaminyl and glutamate cyclases
08/24/2006	US20060189522 Modification of feeding behaviour
08/24/2006	US20060189521 Human Liver Regeneration Associated Protein and the Use Thereof
08/24/2006	US20060189520 Treatment of diabetes
08/24/2006	US20060189519 Anti-angiogenic fragments fo pigment epithelium-derived factor (pedf)
08/24/2006	US20060189518 Preventing/remedies for cancer
08/24/2006	US20060189517 Cross-linked glycopeptide-cephalosporin antibiotics
08/24/2006	US20060189516 Method for producing cross-linked hyaluronic acid-protein bio-composites
08/24/2006	US20060189515 Drug delivery across the blood-brain barrier using polypeptides; neurological diseases; aprotinin
08/24/2006	US20060189514 Compositions and uses of a galectin for treatment of dry eye syndrome
08/24/2006	US20060189513 A lactoferrin having an N-terminal lactoferrin variant in combination with an effective amount of an antidiabetic drug useful for decreaing blood levels of glucose and insulin thereby treating diabetes mellitus. monitoring the level of glycosylated hemoglobin (HbA1c); delayed release; hyperglycemia
08/24/2006	US20060189512 Compositions containing botanical extracts rich in phlorizin and methods for using such compositions in blood glucose modification and to affect aging
08/24/2006	US20060189511 Method for cytoprotection through mdm2 and hdm2 inhibition
08/24/2006	US20060189001 Ssx-2 peptides presented by hla class II molecules
08/24/2006	US20060188990 Novel prostate tumor-specific promoter

1 ... 1220 1221 1222 1223 1224 1225 1226 1227 1228 1229 1230 1231 1232 1233 1234 1235 1236 1237 1238 1239 1240 ... 3163